|
|
Article: Amylin obtains license from NIH for novel use of Exendin-4.(Amylin Pharmaceuticals Inc., National Institutes of Health)(Brief Article)
- Article from:
- BIOTECH Patent News
- Article date:
- March 1, 2001
CopyrightCOPYRIGHT 2001 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amylin Pharmaceuticals, Inc. (San Diego, CA; 858-552-2200) announced that it has signed a license agreement with the National Institutes of Health (NIH). Under the agreement, Amylin obtains exclusive worldwide rights to patent applications directed to a novel use of exendin-4 to convert non-insulin producing cells into insulin producing cells. Amylin agreed to pay license fees to the NIH and will perform research relating to this novel use.
"The promise of turning non-insulin producing cells into insulin producing cells, also known as beta cell neogenesis, is very exciting," said Alain Baron, MD, Vice President of Clinical Research at Amylin Pharmaceuticals. Dr. ...
Related newspaper, magazine, and journal articles:
|
|
Article: Regimen Offers Hope for Some Diabetics; Injection of Insulin- ...
The Washington Post;
April 30, 2002 ;
700+ words
... ... Experimental transplants of insulin-producing cells, using a regimen recently ... recovery of clumps of insulin-producing cells called islets from the pancreas ... Harlan, a researcher at the National Institutes of Health who has transplanted ...
|
|